Catalio Capital Management, LP — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

AdvanCell Isotopesadvancell.com.au inJun 2026

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)in Aaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsBain Capital Life Sciences Proto Axiom Sanofi Ventures SV Health Investors Tenmile Abingworth +2 more

Georgiamunegeorgiamune.com inJul 2026

Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases.

BiotechDeep TechHealthtechGaithersburg, US

Samir N. Khleif(Founder & CEO)inRamy Ibrahim(Chief Medical and Strategy Officer)inMikayel Mkrichyan(Senior Vice President of Science and Discovery)Sarah Sharman(Vice President of IP Legal Affairs)

BoardSean Parker(Director)Elena Viboch(Director)in

Co-investorsGeneral Catalyst HAWKTAIL Lauder Partners Prevail Venture Capital Alexandria Catalio Capital Management +3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.